Monte Carlo optimization of a neutron beam from **5** MeV ⁹Be(p,n)⁹B reaction for clinical BNCT

I.Postuma^{1,*}, S.Bortolussi², N.Protti¹, S.Fatemi^{1,2}, S.J. González^{3,4}, L. Provenzano^{3,4}, G.Battistoni⁵ and S. Altieri 1,2

1) Istituto Nazionale Di Fisica Nucleare (INFN), Unit of Pavia, Italy. 2) Department of Physics, University of Pavia, Italy. 3) Cómisión Nacional de Energía Atómica (CNEA), Argentina. 4) CONICÉT, Argentina. 5) Istituto Nazionale Di Fisica Nucleare (INFN), Unit of Milan, Italy.

Objectives

Tailor a neutron beam for clinical Boron Neutron Capture Therapy (BNCT) from 5 MeV protons interacting on a beryllium target :

2 - Neutron Source

We tested MCNP and PHITS models and libraries for the reaction ${}^{9}\text{Be}(p,n){}^{9}\text{B}$. The results were then compared with experimental results [1]:

3 - Moderating material

We want an epithermal neutron beam with a flux greater than $10^9 \text{ cm}^{-2} \text{ s}^{-1}$. The neutron flux along the beam axis of various bulk material is:

6 - Radio-protection

Beam number 2 was used to simulate dose distribution in air in the whole treatment room and it was proven to have a high radial neutron contamination. Consequently, the BSA was further modified to better collimate the beam, providing an acceptable result. The final beam thus obtained was again tested on the clinical case to prove that its performances at clinical level have not changed dramatically

- By following the IAEA guidelines, select the material that best modifies the initial neutron energy spectra for clinical BNCT. • Pick the Beam Shaping Assembly (BSA) that best suits the IAEA parameters and the dose evaluation in Snyder phantom.
- Test the BSA on a real clinical case with a Treatment Planning System and choose the most performing neutron beam.
- Finally, investigate the dose distributions due to the neutron beam in the whole treatment room.





Consequently, we implemented a neutron source distributed in the target, based on experimental double differential spectra [1].

It resulted that the **most perform**ing material is AlF₃. Further checks on fast neutron and photon contamination confirmed AlF_3 as the best bulk material for our set-up.

Important Result

To tailor an epithermal neutron beam, one starts by using IAEAs parameters as guidelines. Then it is important to test the neutron beam on real clinical cases. Finally, the optimization must take into account the dose distribution in the environment and the radioprotection issues.



7 - Conclusioni

1 - Introduction

Boron Neutron Capture Therapy (BNCT) is an experimental radiotherapy that uses the combination of neutron irradiation and ¹⁰B to treat neoplasms. Many clinical trials were performed worldwide with promising result using research nuclear reactors as neutron sources. Anyhow, these machines are very difficult to be installed in hospitals. This issue can now be overcome by using intense-current proton accelerators, which coupled with beryllium or lithium targets yield more than 10^{14} neutron per second. These accelerators are more compact, easy to operate and maintain, and can boost the development of dedicated BNCT clinical centers.

4 - Physical parameters

The IAEA-TECDOC-1223 proposes three physical parameters to evaluate the quality of an epithermal neutron beam: epithermal flux ϕ_{epi} , fast neutron contamination D_n/ϕ_{epi} and gamma photon contamination D_q/ϕ_{epi} . In the table below IAEA recommendations are compared to the figures of merit of 4 different BSA geometries, containing AlF_3 as bulk moderating material.

5 - Clinical comparison

We used NCTPlan [2] Treatment Planning System (TPS) on a real clinical osteosarcoma case. The figure below shows Dose Volume Histograms (DVH) for the tumor and for the organ at risk (skin) due to the 4 beams. The DVH plot tells us that the BSA delivering the highest dose to the tumor *prescrib*ing the same maximum skin dose is number 2. The next step is to test this beam from the radio-protection point of view.

This work shows that the tailoring of a BNCT beam for clinical application is a very complex task, that cannot be completed only by the calculation of IAEA figures of merit in air. Treatment planning calculations and dosimetric evaluation outside the clinical target are important because they can have a strong influence on the final beam. These calculations led to a BNCT epithermal neutron beam that show optimal performance in the tumour and satisfies many dosimetric requirements.

References

- [1] S Agosteo, P Colautti, J Esposito, A Fazzi, MV Introini, and A Pola.
- Characterization of the energy distribution

Italian National Institute of The Nuclear Physics (INFN) designed and manufactured a Radiofrequency Quadrupole proton accelerator (RFQ), which delivers 5 MeV protons with 30 mA current in a Continuous Wave (CW) mode and it is coupled to a beryllium target. This accelerator could be installed at Centro Nazionale di Adroterapia Oncologica (CNAO) in Pavia.

In this work, with the aid of Monte Carlo (MC) simulations, we show the design of the neutron moderator that couples the INFN-RFQ to a clinical BNCT facility.

#	ϕ_{epi}	$\frac{D_n}{\phi_{epi}}$	$rac{D_{\gamma}}{\phi_{epi}}$
	$(10^9 \text{ cm}^{-2} \text{ s}^{-1})$	(10^{-13})	Gy cm 2)
1	2.6	7.1	6.3
2	2.8	8.9	3.7
3	2.6	9.0	3.9
4	1.6	7.6	2.8
IAEA	> 1	< 2.5	< 2.5

The results shows that none of the

beams strictly comply with IAEA

guidelines. However, these beams

have been tested in treatment

planning simulations to eval-

uate their dosimetric perfor-

mance.

•

100 -80 Volume + 1 treatment time 25 **60** 2 treatment time 21 3 treatment time 23 40^{-1} 4 treatment time 43 % 20 0+ 0 100 20 40 60 80 Dose (Gy)

Contact Information

• Web:

www2.pv.infn.it/~postuma/ • Email: ian.postuma@pv.infn.it • Phone: +39 0382 987635

of neutrons generated by 5 meV protons on a thick beryllium target at different emission angles.

Applied Radiation and Isotopes, 69(12):1664-1667, 2011.

[2] SJ González.

Nctplan, the new pc version of macnetplan: improvements and verification of a bnct treatment planning system. In Proc. 10th Int. Congress on Neutron Capture Therapy for Cancer, Essen, Germany, 2002, 2002.





Con il contributo del Ministero degli Affari Esteri e della Cooperazione Internazionale, Direzione Generale del Sistema